Cornerstone Investment Partners LLC Sells 2,136 Shares of Elevance Health, Inc. $ELV

Cornerstone Investment Partners LLC trimmed its position in Elevance Health, Inc. (NYSE:ELV) by 1.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 167,102 shares of the company’s stock after selling 2,136 shares during the period. Elevance Health accounts for 2.3% of Cornerstone Investment Partners LLC’s investment portfolio, making the stock its 24th biggest position. Cornerstone Investment Partners LLC owned about 0.08% of Elevance Health worth $58,578,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Sei Investments Co. raised its position in shares of Elevance Health by 7.7% during the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after buying an additional 11,745 shares in the last quarter. Glenview Trust co raised its position in shares of Elevance Health by 41.5% during the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock valued at $630,000 after buying an additional 475 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of Elevance Health by 6.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after buying an additional 4,272 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Elevance Health by 5.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after purchasing an additional 2,012 shares during the period. Finally, Quantinno Capital Management LP raised its position in Elevance Health by 111.8% in the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after purchasing an additional 23,180 shares during the period. 89.24% of the stock is owned by institutional investors.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an “outperform” rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird’s update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Robert W. Baird lifted their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday. Sanford C. Bernstein lifted their target price on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday. The Goldman Sachs Group lifted their target price on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Elevance Health from $332.00 to $363.00 and gave the stock a “hold” rating in a research report on Thursday. Finally, UBS Group set a $400.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Eleven equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $380.42.

Elevance Health Price Performance

ELV stock opened at $344.64 on Monday. The firm’s 50-day moving average price is $308.96 and its two-hundred day moving average price is $331.22. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $427.54. The stock has a market capitalization of $74.84 billion, a price-to-earnings ratio of 14.66, a PEG ratio of 2.06 and a beta of 0.49. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the company earned $11.97 earnings per share. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 26.81 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s payout ratio is presently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.